10-Q: Rockwell Medical Q2 Loss Widens on DaVita Sales Decline

Rockwell Medical, Inc. reported a significant decline in net sales and a widened net loss for the second quarter and first half of 2025, primarily due to a major customer transitioning to a new supplier.

Summary

• Net sales for the three months ended June 30, 2025, decreased by 38% to $16.1 million, down from $25.8 million in the prior year, primarily due to a $9.9 million reduction in sales to DaVita.
• Net sales for the six months ended June 30, 2025, decreased by 28% to $35.0 million, down from $48.5 million in the prior year, primarily due to a $14.6 million reduction in DaVita sales.
• Gross profit for the three months ended June 30, 2025, was $2.5 million, a 45% decrease from $4.6 million in the prior year.
• Gross profit for the six months ended June 30, 2025, was $5.5 million, a 28% decrease from $7.6 million in the prior year.
• The company reported an operating loss of $1.3 million for the three months ended June 30, 2025, compared to an operating income of $0.5 million in the prior year.
• The net loss for the three months ended June 30, 2025, widened to $1.5 million, compared to a net income of $0.3 million in the prior year.
• The net loss for the six months ended June 30, 2025, widened to $3.0 million, compared to a net loss of $1.4 million in the prior year.
• Net cash used in operating activities increased to $1.6 million for the six months ended June 30, 2025, from $0.9 million in the prior year.
• As of June 30, 2025, cash, cash equivalents, and available-for-sale investments totaled approximately $18.4 million, with net working capital of $20.7 million.
• The company entered into a new multi-million dollar, three-year product purchase agreement with Innovative Renal Care (IRC) for hemodialysis concentrates and the DAMX45 dry acid concentrate mix system.
• A revenue covenant under the loan agreement with Innovatus Life Sciences Lending Fund I, LP, was not satisfied in Q2 2025 due to the loss of DaVita business but was remediated by submitting an updated financial projection.

Sentiment

Score: 3

Explanation: The company experienced significant financial deterioration, primarily due to the loss of a major customer. While a new customer was secured and a loan covenant issue resolved, the overall trend is negative, and future capital raises are anticipated, which could lead to dilution.

Positives

• Secured a new multi-million dollar, three-year product purchase agreement with Innovative Renal Care (IRC), a significant dialysis service provider.
• Successfully remediated a revenue covenant non-compliance with Innovatus by submitting an updated financial projection, maintaining compliance with loan terms.
• Management believes the company has sufficient funds to meet its operating requirements for at least the next twelve months.
• Implemented cost containment activities to manage expenses.

Negatives

• Experienced a significant 38% decrease in net sales for the three months ended June 30, 2025, and a 28% decrease for the six months, primarily due to a $14.6 million reduction in sales from DaVita.
• Gross profit declined by 45% for the three months and 28% for the six months ended June 30, 2025.
• Shifted from an operating income of $0.5 million in Q2 2024 to an operating loss of $1.3 million in Q2 2025.
• Net loss widened to $1.5 million for Q2 2025 and $3.0 million for the first half of 2025.
• Net cash used in operating activities increased to $1.6 million for the six months ended June 30, 2025, indicating higher cash burn.
• All deferred revenue relating to international distribution and license agreements was recognized, and all such license agreements have been terminated, leading to a $0.2 million write-off of Triferic raw materials inventory.
• Research and product development related to Triferic was paused in 2023.

Risks

• Uncertain global macroeconomic environment, including changes in U.S. trade policies, tariffs, and other trade restrictions.
• Instability in global capital and credit markets, including recent bank failures in the United States.
• Supply chain weaknesses and instability in the geopolitical environment (e.g., Russian invasion of Ukraine, Middle East conflict, other political tensions).
• Potential for recession fears, rising interest rates, foreign exchange volatility, and inflationary pressures to negatively affect future operations.
• Inability to secure additional debt or equity financing on favorable terms, or at all, which may be required to sustain operations and execute strategic plans.
• Potential for significant dilution of stockholders' interests if additional capital is raised through equity financings.
• Limitations on incurring additional debt due to the Securities Purchase Agreement with DaVita, requiring DaVita's consent for certain types of debt.
• Risk of non-compliance with covenants under the Loan Agreement with Innovatus, despite recent remediation.
• Dependence on the ability to execute the growth strategy of the hemodialysis concentrates business and maintain sales with existing customers.
• Uncertainty regarding the outcome of ongoing discussions with DaVita for potential contract extension and/or future volume commitments.
• Inability to achieve sustained profitability.
• Inability to identify, develop, in-license, or acquire new products to develop the renal care product portfolio.

Future Outlook

Management believes the company currently has sufficient funds to meet its operating requirements for at least the next twelve months. Operational plans include reviewing current strategies, acquiring new customers, and implementing cost containment activities. The company may require additional capital and plans to use the remaining $21.1 million available under its at-the-market (ATM) facility or other financing methods if needed. Discussions with DaVita are ongoing regarding a potential contract extension and/or future volume commitments. The company is also evaluating the full effects of the recently enacted U.S. federal statute P.L. 119-21 (tax and spending policies) on its financial statements, though it does not anticipate a material impact on the six months ended June 30, 2025, operating results.

Management Comments

• "Management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report."
• "The Company continues to review its operational plans and execute on the acquisition of new customers, and has implemented cost containment activities."
• "There can be no assurance that these discussions [with DaVita] will yield a successful outcome for Rockwell."
• "The Company is currently evaluating the full effects of the Act [P.L. 119-21] on its condensed consolidated financial statements."

Industry Context

Rockwell Medical operates in the hemodialysis market, a critical sector for end-stage kidney disease treatment, primarily serving freestanding outpatient dialysis centers, hospital-based centers, skilled nursing facilities, and home care. The company is a significant supplier of liquid and dry, acid and bicarbonate concentrates in the United States. The loss of a major customer like DaVita highlights the concentration risk within the industry, while the new agreement with Innovative Renal Care (IRC) demonstrates continued efforts to diversify and secure market share amidst competitive pressures.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against industry standards.

Corporate Governance

Legal Proceedings

• The company may be involved in certain routine legal proceedings from time to time before various courts and governmental agencies.
• The resolution of these pending proceedings is not expected to have a material effect on the company's operations or consolidated financial statements in the period in which they are resolved.

Related Party Transactions

• DaVita, Inc. is a related party due to the issuance of Series X Preferred Stock to them on April 6, 2022.
• The Securities Purchase Agreement (SPA) with DaVita limits the company's ability to incur additional debt (beyond purchase money loans, a working capital line up to $5.0 million, or refinancing existing debt) without DaVita's consent, as long as DaVita holds more than 50% of its original investment in Series X Convertible Preferred Stock.
• Innovatus Life Sciences Lending Fund I, LP, is a party to the Loan Agreement, and the company issued a warrant to Innovatus on January 2, 2024, in connection with the Third Amendment to the Loan and Security Agreement.

Stakeholder Impact

• **Shareholders**: Face potential dilution from future equity capital raises (e.g., ATM facility) and negative impact on share price due to significant revenue decline, widening losses, and increased cash burn. The loss of a major customer (DaVita) is a direct negative impact.
• **Employees**: Continue to benefit from stock-based compensation plans (RSUs, stock options), but the company's deteriorating financial performance could affect future compensation, job security, or morale.
• **Customers**: The loss of DaVita as a major customer is a significant event, but the new agreement with Innovative Renal Care (IRC) provides some continuity and diversification of the customer base.
• **Creditors**: The remediation of the revenue covenant breach with Innovatus is positive for maintaining loan compliance, but ongoing losses and increased cash usage from operations could raise concerns about the company's long-term financial health and ability to service debt.

Next Steps

• Continue to review operational plans and execute on the acquisition of new customers.
• Implement cost containment activities.
• Engage in ongoing discussions with DaVita for a potential contract extension and/or future volume commitments.
• Evaluate the full effects of the U.S. federal statute P.L. 119-21 (tax and spending policies) on the condensed consolidated financial statements.
• Potentially raise capital using the $21.1 million available under the ATM facility or other financing methods.
• Focus efforts on increasing market share, broadening the product portfolio, right-sizing product pricing, improving gross margins, and growing the business through organic and inorganic opportunities.

Key Dates

Recommendation

The company reported a substantial decline in revenue and gross profit, coupled with a widening net loss and increased cash burn from operations. The loss of DaVita, a major customer, significantly impacted financial performance, and while a new customer was secured, it does not fully offset the decline. The company anticipates needing to raise additional capital, which could lead to further shareholder dilution. Despite remediating a loan covenant breach, the overall financial trajectory is negative, indicating significant operational challenges and a deteriorating financial position.

Keywords

Hemodialysis, Dialysis Concentrates, Renal Care, Medical Devices, Healthcare, SEC Filing, Quarterly Report, RMTI, DaVita, Innovatus, Financial Results, Product Sales